Search
Chairs and members
Chair (2024–2027)
Elizabeth Macintyre, Hôpital Necker-Enfants Malades et Université Paris, France
Vice-Chair (2024–2027)
Margarita Guenova, National Specialised Hospital for Active Treatment of Haematological Diseases, Belgium
Steering Committee (2024–2027)
Monika Brüggemann, University Hospital Kiel, Germany (ESHLO)
Francesco Buccisano, Tor Vergata University of Rome, Italy (SWG on Diagnosis…
EHA Guidelines on Recommendations for Pregnancy in Rare Inherited Anemias
EHA and the Scientific Working Group on Red Cells and Iron organized the first online workshop on the EHA Guidelines: “Recommendations for Pregnancy in Rare Inherited Anemias”.
Read moreMeet our Volunteers of the Month: Elizabeth, Francesca and Verena
Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik.
Read moreMeet our Volunteers of the Month: Elizabeth, Francesca and Verena
Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik.
Read moreSWG Grant-funded projects, 2024
In November and December of 2023, SWGs were invited to develop project ideas and apply for a 2024 SWG Grant. ApplicationsWe received 11 different applications from 9 SWGs. This was two more applications than we received in 2022.
Read moreEHA returns to Cairo with the Highlights of the 24th EHA Congress
The 4th Highlights of Past EHA (HOPE) Middle East & North Africa (MENA) took place (for the third time) in Cairo, Egypt, organized in collaboration with the Pan Arab Hematology Association (PAHA) and hosted by the Egyptian Society of Hematology…
Read moreGuidelines for hematologists
For guidance regarding COVID-19, see FAQ by the EHA SWG on Infections
EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases.
Meet our first Physician Scientist Research Grant winner
In 2018 the Physician Scientist Research Grant was awarded for the first time.
Read moreGdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.
Expert opinions for specific non-malignant hematologic diseases
Red Cells and Iron
Hemoglobinopathies: Sickle Cell Disease and Thalassemia
Sickle Cell Disease Association of America (SCDSS)
Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity
Italian Society of Thalassemia and Hemoglobinopathies
Thalassemia and Hemoglobin disorders Italian Society
Thalassemia International Federation (TIF)
The COVID-19…
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- »